Dysregulation of histone methylation is deeply involved in the pathogenesis of MM, and recent preclinical studies have demonstrated the antimyeloma effects of inhibitors of EZH2, a H3K27 methyltransferase7–9, and DOT1L, a H3K79 methyltransferase10,11. This evidence concerns the gene DOT1L and Miyoshi myopathy.